Atossa Therapeutics Granted Additional Patent Protection For Endoxifen
Portfolio Pulse from Happy Mohamed
Atossa Therapeutics (NASDAQ: ATOS) has been granted a new patent (No. 11,680,036) by the USPTO for enterically encapsulated endoxifen compositions formulated as a suspension. The patent covers all liquid suspension formulations suitable for oral administration and pediatric applications.
June 21, 2023 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics has been granted a new patent for enterically encapsulated endoxifen compositions, potentially expanding the therapeutic role of endoxifen beyond breast cancer.
The new patent granted to Atossa Therapeutics covers suspension formulations of endoxifen, which may have potential therapeutic applications beyond breast cancer and mammographic breast density. This could lead to an expansion of the company's product pipeline and potentially increase its market value. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100